Hartmuth C. Kolb
Hartmuth Christian Kolb (born August 10, 1964) is a German chemist. He is considered one of the founders of click chemistry. Early life and career. After graduating from high school in Marsberg in 1983, Kolb studied at the University of Hanover. He received his doctorate as an academic student of Steven Ley at Imperial College London with a thesis on preparative organic chemistry ("Synthesis of the decalin fragment of azadirachtin"). As a postdoctoral fellow he worked with Barry Sharpless at the Scripps Research Institute in La Jolla, California. He then worked in the research department of Ciba -Geigy in Basel from 1993 to 1997 before taking up a managerial position at Coelacanth Corporation, founded by Sharpless and A. Bader in Princeton, New Jersey. Coelacanth was eventually acquired by Lexicon Pharmaceuticals. In 2002, Kolb obtained an associate professorship in the Department of Chemistry at the Scripps Research Institute. Kolb later obtained a professorship at the University of California, Los Angeles. In 2004 Kolb returned to industry and became Vice President of Molecular Imaging Biomarker Research at Siemens Healthcare in Culver City, California. In 2013, Siemens sold two of the substances developed there to Eli Lilly and Company. Simultaneously , Kolb joined Avid Radiopharmaceuticals in Philadelphia, Pennsylvania, a subsidiary of Eli Lilly and Company, as vice president of research. Kolb also acts as managing director of a manufacturer of animal feed flavorings in his home town of Marsberg. Work. Together with Barry Sharpless and M.G. Finn, Kolb developed the concept of click chemistry, an approach to simplify synthesis by focusing on a few chemical reactions that are similar in nature. The associated scientific publication Click chemistry: diverse chemical function from a few good reactions has been cited more than 14,000 times (as of 2021). Kolb refined the method by combining  it as in-situ click chemistry with microfluidic processes. This makes it particularly easy to synthesize new inhibitors for various enzymes. Kolb's more recent work deals with the synthesis of new tracers for positron emission tomography (e.g. for detecting the tau protein in Alzheimer's disease) and with the clinical testing of these tracers.